跳至主要内容
临床试验/NL-OMON44715
NL-OMON44715已完成4 期

Prevention of exacerbations in patients with COPD through vitamin D supplementation: a randomized controlled trial - COPD and vitamin D (PRECOVID)

Vrije Universiteit Medisch Centrum0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Written informed consent
  • Aged * 40 years
  • Postbronchodilator FEV1/FVC<0,70 and FEV1<80% (GOLD stages II-IV) and diagnosis COPD confirmed by a medical doctor.
  • Minimum of 10 packyears of smoking
  • Vitamin D deficiency (defined as a serum 25-hydroxyvitamin D < 50 nmol/l). Lab value should not be older than 8 weeks.
  • Ability to comply with all study requirements

排除标准

  • Pregnant or lactating women, or subjects who intend to become pregnant within the study period
  • Self-reported history of hypercalciemia or nephrolithiasis
  • Self-reported presence of sarcoidosis
  • Severe vitamin D deficiency (serum 25-hydroxyvitamin D <15 nmol/l)
  • Life expectation of less than 6 months on the basis of concurrent disease
  • Interfering malignant diseases
  • Diagnosed osteoporosis
  • Diagnosed asthma
  • Diagnosed chronic kidney disease stage 4 or higher (eGFR <= 29ml/min/1.73m2)
  • Serious mental impairment i.e. preventing to understand the study protocol or comply with the study aim; potentially unreliable patients and those judged by the investigator to be unsuitable for the study
  • Use of maintenance dose oral corticosteroids
  • Use of multivitamin supplement or vitamin D supplement which contains more than 400 IU per day
  • Current participation in a clinical rehabilitation programme. Patients can be included from the day after they have finished the programme.

研究者

相似试验

Prevention of exacerbations in patients with COPD... | 临床试验